SCHEMBL724878

SCHEMBL724878

Cn1cc(-c2ccnc3cc(-c4ccc5cc[nH]c5c4)oc23)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.47
AURKB Q96GD4 3/20 0.46
AURKA O14965 2/20 0.46
INCENP Q9NQS7 2/20 0.46
TPX2 Q9ULW0 2/20 0.46
BRAF P15056 1/20 0.43
PDE4C Q08493 1/20 0.41
MAPK1 P28482 2/20 0.39
WNT1 P04628 1/20 0.38
GSK3B P49841 1/20 0.38
DYRK1A Q13627 1/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38
BRD4 O60885 1/20 0.37
PRKDC P78527 1/20 0.37
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
KCNH2 Q12809 3/20 0.36
MPO P05164 1/20 0.36
TPO P07202 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL724531 0.93 LRRK2 (0.56) LRRK2AURKBAURKAINCENPTPX2
SCHEMBL725356 0.87 BRAF (0.43) AURKBAURKAINCENPTPX2BRAF
SCHEMBL721989 0.85 ACVR1 (0.44) LRRK2AURKBAURKAINCENPTPX2
SCHEMBL10268949 0.84 AURKB (0.46) LRRK2AURKBAURKAINCENPTPX2
SCHEMBL10268110 0.82 MET (0.44) LRRK2AURKBAURKAINCENPTPX2
SCHEMBL16817167 0.81 LRRK2 (0.45) LRRK2AURKBAURKAINCENPTPX2
SCHEMBL725127 0.80 WNT1 (0.42) LRRK2AURKBAURKAINCENPTPX2
SCHEMBL722397 0.79 AURKB (0.44) LRRK2AURKBAURKAINCENPTPX2
SCHEMBL723727 0.79 FYN (0.40) LRRK2AURKBAURKAINCENPTPX2
SCHEMBL724102 0.79 AURKB (0.38) LRRK2AURKBAURKAINCENPTPX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB LRRK2 787/4885AURKB 1443/4885AURKA 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.